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The approach to treating a rare disease is different to that taken for more common diseases.
Small patient cohorts alter clinical trial design and limit enrollment, and the picture for rare
lung diseases is further complicated by the fact that most are composed of a variety of clinical
phenotypes. Since the outcome measures of lung impairment have considerable test-to-test
variability, potential new therapies face a substantial challenge. In this paper we will review
the current sources of clinical data for rare lung diseases and the regulatory challenges
encountered by their treatment, with particular reference to alpha1-antitrypsin deficiency,
lymphangioleiomyomatosis, cystic fibrosis, and pulmonary alveolar proteinosis. Strategies will
also be identified for the better utilization of available data from patients with rare lung
diseases, recognizing that the development cost of new therapies and the number of patients
who will ultimately use them may not be aligned. Also important is improved communicationlogia, Fondazione IRCCS Policlinico San Matteo, Piazza Golgi 1, 27100 Pavia, Italy. Tel.: þ39 0382
o.pv.it (M. Luisetti).
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760 M. Luisetti et al.between patients and their organizations, basic researchers, clinicians and their registries,
drug developers, regulators such as the European Medicines Agency, and national health
services. At present, licensing and reimbursement requirements are not aligned, either nation-
ally or internationally, and variations also exist in drug availability between countries because
of different national licensing and reimbursement rules. The changes needed to optimize Euro-
pean rare lung disease therapies include a commitment to develop empowered patient
communities as advocates for therapy, the development of novel trial designs with new
endpoints, and for regulatory bodies to be willing to accept nontraditional models of efficacy
for orphan drugs.
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Randomized, double-blind, placebo-controlled clinical
trials are the gold standard for assessing the therapeutic
effect of any drug. However, in assessing therapies for rare
diseases with limited numbers of affected patients, it is
often not achievable to recruit a critical sample size in
order to meet this gold standard. Small patient populations
and rare or variable phenotypes make it difficult to enroll
sufficient patient numbers to randomized clinical trials,
leading to a lack of statistical power. Therapies may fail to
meet traditional measures of efficacy.
In the case of rare diseases, the patients, as well as
being low in number, are often isolated and dispersed,
resulting in further patient recruitment challenges. There is
also insufficient clinical knowledge and poor recognition of
rare conditions by the medical community that often leads
to a delay in the diagnosis and identification of patients.
Furthermore, there is a paucity of quality patient infor-
mation and little research is carried out compared with
more common diseases. Those who suffer from orphan
diseases, together with their immediate families, may feel
isolated and may receive inadequate attention and thus
care. It is clear that an inequality of healthcare provisionexists compared with other conditions, and there is often
a lack of interest from drug developers when they are faced
with a lengthy time period and difficulties in obtaining
sufficient clinical evidence for regulatory approval of their
products. There may be an imbalance between the devel-
opment costs of bringing a drug into clinical use and the
expected return for the high cost of development. In fact,
over 95% of rare diseases still do not have a specific
treatment.1
The purpose of this article is to review and broaden the
discussion on current sources of clinical data for rare lung
diseases and the regulatory challenges that treatments for
the disorders encounter. It is based on a roundtable
meeting attended by the 8 authors in December 2010 where
these issues were discussed. In the paper we will consider
that the requirements for demonstrating clinical effec-
tiveness of drugs may have to be more flexible in rare
diseases compared with common conditions. We will put
forward perspectives and identify strategies for the better
utilization of data from patients with rare lung diseases.
For example, consideration should be given to the valida-
tion of new outcome parameters for clinical trials that
correlate with classically used endpoints, but are more
sensitive, hence requiring a smaller sample size. Other
sources of data and tools should be utilized, such as patient
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studies, or studies with novel designs.
The article will also review the need for more aligned
clinical, licensing, and reimbursement approaches to
enhance the level of clinical evidence in these diseases,
and will discuss how access to therapies can be improved
and accelerated for patients. Drawing upon our experi-
ences in the respiratory disorders alpha1-antitrypsin (AAT)
deficiency, cystic fibrosis (CF), pulmonary alveolar protei-
nosis (PAP), and lymphangioleiomyomatosis (LAM), in
particular, we will propose alternative approaches to
improve the accessibility of therapies for patients in Europe
affected by rare disorders.
Orphan drug legislation
The US Rare Diseases Act of 2002 established the National
Institutes of Health (NIH) Office of Rare Diseases Research.2
For this purpose, a rare disease was defined as one that
affects fewer than 200,000 individuals in the United States
(less than 1 in approximately 1500). There are over 7000
such diseases and conditions in the United States.3 The EU’s
definition of a rare disease is a life-threatening or chroni-
cally debilitating condition of low prevalence, affecting 5
or fewer people in every 10,000 (approximately 250,000
individuals in total).4 About one half of these rare diseases
affect children, and about 80% are a result of a genetic
defect (others being degenerative or proliferative disor-
ders). The total number of rare diseases is estimated to be
in the order of 5000e8000 within the EU, and it is thought
that 6e8% of the population will be affected by a rare
disease at some stage in their life. Overall, 25 million North
Americans and 30 million Europeans are estimated to be
suffering from a rare disease,5 and approximately 250 new
conditions are identified each year.6 Some diseases occur so
infrequently that there may be 50 or fewer sufferers in
a single country. Nevertheless, extrapolated globally, this
may amount to many thousands. Examples of rare lung
diseases and their prevalence are provided in Table 1.
There is a difference between the definition of a rare
disease and a neglected disease. The latter, while it may be
rare, may also be a common yet overlooked condition. The
concept of a neglected disease is a lack of interest in theTable 1 Examples and prevalence of rare lung diseases.
Disease Approximate prevalence
(per 10,000 population)
CF EU: 0.7377
US: 0.7977
AAT deficiency
(PiZZ genotype)
Europe: 2e2.58
US: 3.39
LAM Worldwide: 0.01 (women)10
PAP Worldwide: 0.03711
Children’s interstitial
lung disease
UK and Ireland: 0.03612
Idiopathic pulmonary fibrosis Worldwide: 2 (men);
1.3 (women)11
Small-cell lung cancer Worldwide: 0.511condition rather than just its rarity. In general, new antibi-
otics are not being developed for some of the more common
neglected diseases, tuberculosis being such a case.
An orphan drug or medicinal product is defined in the EU
as being intended for the diagnosis, prevention, or treat-
ment of a life-threatening or chronic debilitating rare or
orphan disease (as described above).13 Orphan drug status
also applies to a medicinal product intended for the diag-
nosis, prevention, or treatment of a life-threatening, seri-
ously debilitating condition that, without incentives, is
unlikely to realize sufficient financial return to justify the
investment required for its commercialization. Addition-
ally, in order for the drug to qualify for orphan status, there
should either be no authorized satisfactory method of
diagnosis, prevention, or treatment of the condition in
question or, if such method exists, the medicinal product
should be of significant benefit to those affected by that
condition (i.e., improved efficacy, safety, or ease of
administration, compared with existing treatments).
TheUSOrphan Drug Act, which came into effect in 1983,14
and which has been followed by the development and
marketing of more than 350 biologic products and drugs,15
paved the way for the introduction of legislation in the EU
in 2000 (EU Regulation [EC] No 141/2000).13 The purpose of
the EU legislation,which applies to all 27member states,was
to provide incentives for the research, development, and
marketing of designated orphan medicinal products. Orphan
drug status granted by the European Commission gives
marketing exclusivity throughout the EU for 10 years after
approval, with the regulation being administered by the
Committee on Orphan Medicinal Products (COMP) of the
European Medicines Agency (EMA). A product originally
developed and approved for another indication can gain
orphan drug status for a different indication. Examples
include sildenafil and iloprost, which have been granted
marketing authorization for pulmonary hypertension. After
10 years of orphan drug legislation in the EU, approximately
800 products have been granted orphan status, including 47
for rare lung diseases (Table 2); EU marketing authorization
has been granted for 6 of these 47 products.
The EU legislation does not overcome the barriers to the
initial development of new drugs for rare diseases but it can
exempt the product’s sponsor from fees payable to the
EMA, with small- and medium-sized enterprises being given
the most incentives (Table 3). Other assistance includes the
provision of scientific advice and protocol assistance to the
pharmaceutical company on the manufacturing, preclin-
ical, and clinical evaluation (including study design, sample
size, establishing endpoints, and statistical analyses). This
advice can be used for every aspect of the development of
a drug. The onus is on the pharmaceutical company to
actively seek this advice from the Scientific Advice Working
Party (SAWP), asking the necessary targeted questions and
proposing ways to investigate the product in order to
demonstrate clinical benefit. The fact that large-scale
randomized clinical trials are not feasible when evalu-
ating treatment of rare diseases is recognized. The SAWP
and, subsequently, the Committee for Medicinal Products
for Human Use (CHMP) have proven willing to consider
observational studies or the use of surrogate markers as an
alternative to the usual regulatory requirements for the
demonstration of clinical benefit.
Table 2 Summary of orphan medical products designated by the EMEA for lung diseases (as of November 30, 2010).16
Condition/disease Number of medical products
designated as orphan
Prevention/treatment of graft rejection after lung transplant 4
Treatment of acute lung injury 7
Treatment of bacterial lung infection in CF 7
Treatment of small-cell lung cancer 4
Treatment of subtype of non-small-cell lung cancer 1
Treatment of pulmonary lung infection 1
Treatment of idiopathic pulmonary fibrosis 9
Treatment of pulmonary hypertension 14
Total 47
762 M. Luisetti et al.Issues and challenges for rare lung diseases and
their treatment
Disease phenotypes and patient numbers
Although it is common rather than rare, the diagnosis and
treatment of chronic obstructive pulmonary disease (COPD)
is associated with many of the challenges that clinicians
face when presented with a rare lung disease. As a result of
their polygenetic origin, common lung conditions such as
COPD are associated with considerable heterogeneity of
clinical presentation and disease progression; variations are
observed in symptoms, frequency of exacerbations,
response to therapy, rate of disease progression, or
premature death.18 Rather than being considered a single
disease, COPD should be viewed as a syndrome made up of
multiple separate disorders that overlap.19 The diversity of
patient COPD phenotypes included in two large-scale trials,
Understanding Potential Long-Term Impacts on Function
with Tiotropium (UPLIFT)20 and Toward a Revolution in
COPD Health (TORCH),21 likely contributed to neither of
these studies achieving their primary efficacy endpoint
(loss of forced expiratory volume in one second [FEV1] over
time, and reduction in mortality, respectively).Table 3 EMA incentives for pharmaceutical companies to
develop orphan drugs.17
 Scientific advice in protocol development
 Centralized market authorization
 10-year marketing exclusivity
 Financial benefits
e Exemption from fees for protocol assistance and
follow-up
e Exemption from fees for pre-authorization
inspections
e New application fees reduced by 50% (total
exemption for small- to medium-sized enterprises)
e Exemption from postauthorization activities
(small- to medium-sized enterprises only)
e Assistance with translation of product
information documents (small- and medium-sized
enterprises)More recently, stratification of COPD patients according
to disease phenotype has been used to demonstrate effi-
cacy in relatively short-duration studies in smaller numbers
of patients. The benefit of the phosphodiesterase-4 inhib-
itor roflumilast, for example, in reducing the occurrence of
exacerbations in patients with a history of frequent COPD
exacerbations was shown in two placebo-controlled studies
comprising a total of 1537 patients treated for 52 weeks.22
Asthma is another example of a common respiratory disease
with varying severity of symptoms. Eosinophilic inflamma-
tion of the airways is associated with a risk of asthma
exacerbations. A placebo-controlled study in 61 patients
with asthma and airway eosinophilia found a significant
reduction in the number of exacerbations over a 50-week
period associated with the use of an anti-interleukin-5
monoclonal antibody.23 In the light of phenotypic influ-
ence on study outcomes, these are examples of a trend in
the study of different aspects of disease toward more
personalized medicine, and to finding the right population
that will benefit most from a particular treatment.24
The concept of a respiratory disease as a syndrome (with
a specific set of symptoms), and a phenotyping strategy for
investigating treatments, is also relevant to rare condi-
tions. In individuals with severe AAT deficiency, the
development and manifestations of COPD are highly vari-
able. Among patients with the same genotype, some have
reduced lung function and some have normal function,
certain patients are fast decliners, and there are individ-
uals who have bronchiectasis while others may be colonized
with specific airway microflora.25 Correspondingly, in LAM,
there are stable patients and others who decline quickly. In
women with LAM, only about 40% develop renal angio-
myolipomas.26 In the case of PAP, there is a wide range of
symptoms and varying pathophysiologies.27 In CF, some
patients display the classical manifestations of the disease
from infancy and have a relatively poor prognosis, while
others have much milder or even atypical disease mani-
festations and a marked variation in the organs
involved.28,29 Clinical observation shows that siblings with
CF can manifest different phenotypes (both in terms of
disease severity and degree of different organ involve-
ment), despite being affected by the same gene mutations,
presumably due to the presence of gene polymorphisms.
In a number of rare diseases, the clinical phenotype is
more clearly defined than in common diseases, which could
confer an advantage on the study of these conditions. This
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subjects with different phenotypes. Subtypes of rare
diseases can be investigated to find meaningful outcomes
when applying a therapeutic strategy, and by dissecting the
phenotypes it may be possible to demonstrate specific
improvements. For example, molecular phenotyping in PAP
can be carried out to study a particular subtype of the
disease, and, in lung cancer, specific epidermal growth-
factor receptor mutations have been targeted for treat-
ment. In the case of CF, genotype-specific trials of thera-
pies for different types of CF transmembrane-conductance
regulator mutations are being carried out.30,31
In the Multicenter International Lymphangioleiomyoma-
tosis Efficacy and Safety of Sirolimus (MILES) trial, patients
with moderate lung impairment were predefined and
enrolled into the trial; those with normal lung function,
where a signal would not be expected in rate of decline in
FEV1, were not selected.
32 In AAT deficiency, augmentation
therapy has been shown to slow the decline in FEV1, an
effect that was most markedly observed in a small subgroup
of rapid decliners.33e35 Therefore, in rare diseases, the
study population needs to be well characterized (i.e.,
phenotyped and selected carefully) in order to be able to
show a treatment effect, and it is not necessarily the case
that studies with large patient numbers have to be con-
ducted. However, once the biologic effect is proven in
a subgroup of individuals with a specific biomarker that is
sensitive to change, expansion of the therapy to larger
cohorts within the rare disease is sometimes plausible.Clinical trial design e appropriate outcomes
The issues associatedwith conducting clinical trials when only
a limited number of patients are available have been
addressed in guidelines published by the EMA.36 These guide-
lines conclude that “the need for statistical efficiency should
be weighed against the need for clinically relevant/inter-
pretable results; the latter being the most important” and
stress that the regulatory assessment may accept different
approaches if they ensure that the patients’ interests are
protected. Emphasis is placed on the importance of the
sponsor obtaining scientific advice/protocol assistance for the
acceptability of the planned approaches. This may include
a discussion on alternative clinical outcome parameters.
There has been considerable recent research into the
development of biomarkers that could replace the classic
lung function parameters. The ECLIPSE study is a non-
interventional, observational, multicenter, 3-year study. In
addition to the characterization of susceptibility to exac-
erbations,37 the cohort from this study has been used to
evaluate new biomarkers (serum Clara cell secretory
protein-16, serum surfactant protein-D, sputum neutro-
phils, and computed tomography).38e40 In the MILES trial in
LAM, serum levels of vascular endothelial growth factor D
(VEGF-D) were used as a biomarker and a reduction in these
levels was a secondary endpoint.32 Further study is required
to establish that VEGF-D is a biomarker of treatment
response, but such biomarkers, if validated, may be equally
appropriate for other rare lung diseases.
The study of biomarkers is especially relevant when
planning smaller studies in rare diseases. Unfortunately, therequirement for a biomarker to be correlated to mortality
may be too high a hurdle for rare diseases. Therefore, new
biomarkers couldbeborrowed fromsimilar butmore common
lung diseases. For instance, new quality-of-life question-
naires in general COPD could be applied to AAT deficiency.
Another important step forward is the use of computed
tomography (CT) to determine emphysema progression. CT
measurements of lung density are now accepted by the Food
and Drug Agency (FDA) as a primary outcome parameter for
clinical trials in patients with COPD due to AAT deficiency.41
Lung density directly measures the emphysema caused by
AAT deficiency, so it may have advantages as an outcome
measure. The optimum use of CT densitometry data for the
assessment of augmentation therapy on the progression of
emphysema in AAT deficiency has been extensively exam-
ined in the EXAcerbations and CT scan as Lung Endpoints
(EXACTLE) trial.33,42 CT was found to be more sensitive than
lung function parameters when measuring the progression of
emphysema in patients with AAT deficiency,33 and also in
patients with COPD caused by smoking.43
The COPD Foundation (a US patient organization)
brought together scientific leadership and the FDA to
establish the COPD Biomarkers Qualification Consortium to
validate outcome measures in COPD. The 5 outcome
measures that seem to have sufficient validity for COPD
research trials include FEV1, CT lung density, inspiratory
capacity, the St George’s Respiratory Questionnaire, and
serum fibrinogen. The measures had to meet criteria for
robustness across studies and correlate with mortality. This
approach could transform COPD trials in the United States,
and implies that the same could be done in Europe, where
a nonregulatory authority would advise on clinical trial
endpoints in order to identify potential outcome measures.
The challenge for rare diseases would be to perform the
numbers of studies required to validate such endpoints. The
CF Gene Therapy Consortium in the United Kingdom, in
common with the CF Foundation in the United States, has
research already in progress to investigate outcome
measures and biomarkers.
Draft EMA guidance on Clinical Investigation of Medicinal
Products in the Chronic Treatment of Patients with COPD is
recommending that efficacy should be demonstrated in two
coprimary endpoints, lung function assessment combined
with symptomatic-based parameters.44 CT densitometry is
proposed as a secondary endpoint. For rare lung diseases,
another potential endpoint not currently under consider-
ation could be treatment failure, with the need to switch to
alternative therapy.
All endpoints have underlying technical issueswith quality
consistency so the need for standardization of endpoints
across different centers is important. However, with better
characterization of the patient populations, use can bemade
of new outcome measures and studies can be powered
according to these endpoints. Patients could be included in
future clinical trials, therefore, who are not selected solely
on the basis of impaired lung function and genotype.Alternatives to randomized clinical trials
Whereas the strongest evidence to demonstrate
efficacy of a therapy is gained during placebo-controlled
764 M. Luisetti et al.randomized clinical trials (RCTs), it may not always be
feasible to obtain these data to evaluate drugs to treat
rare diseases. For example, the size of the patient sample
in AAT deficiency required for such randomized studies
using the traditional physiological measure of FEV1 as the
primary endpoint45 is considered to be impractical, and
due to the relative rarity of AAT deficiency being diag-
nosed, sufficient numbers of patients were not easily
recruited at the time of early studies. A placebo-
controlled crossover trial in LAM was estimated to
require approximately 80 patients to have 90% power to
detect a 50 ml difference in change in FEV1 over 1 year.
46
Furthermore, there are ethical issues in conducting
placebo-controlled clinical trials in countries where there
is already access to treatment.
Under such circumstances, observational data from
patient registries have been used to obtain information on
the efficacy and safety of drugs in rare diseases. The
numbers of patients included are usually greater than those
enrolled in RCTs and patients are not excluded on the basis
of comorbidities or concomitant medications. Furthermore
the long-term longitudinal data collected in observational
studies is more likely to provide information on adverse
reactions and drug interactions.47
In the E.U., conditional marketing authorization may be
granted for treatments for rare diseases, based on the
opinion of the CHMP; the treatments are conditionally
approved and further confirmatory studies are agreed upon
to establish clinical benefit.1 In such cases where regulatory
authorities acknowledge that the acquisition of full data
from a RCT is not feasible, pharmaceutical companies may
be required to collect long-term data in a drug registry as
part of their authorization, and these regulatory databases
will be managed by the company.48 Acceptance of this
approach by the regulatory authorities is dependent upon
these registries being well maintained. This is not always
the case because of the lack of standardization and
completeness of the information entered by different
centers and poor quality control of the data. The quality
and comprehensiveness of data submissions into such
a registry are dependent on the physicians, and they should
be properly supported in this task.48,49
In the E.U., marketing approval has been granted for
orphan drugs, often under exceptional circumstances,
other than on the basis of the findings of classic RCTs.
Examples from an analysis of all European orphan
medicinal product designations from 2000 to 2004 include
an uncontrolled phase II trial, exclusively retrospective
data, and submission of a literature analysis only.50
Furthermore, a number of trials consisted of 50 or fewer
patients. These examples demonstrate that the EMA can
be very flexible regarding trials in rare diseases. On the
other hand, however, the reason why relatively few
designated orphan drugs had gained marketing authori-
zation over the period of the analysis was considered to
be due to the poor quality of the dossiers submitted;
these included such issues as the use of nonvalidated
surrogate markers and trial duration being too short in
relation to the natural history of the disease.50 This
emphasizes the importance of proactivity from the spon-
sors and then seeking scientific advice from the EMA at an
early stage of protocol development.Registries
Patient registries are central to clinical research in rare
diseases and to improving our understanding of these
conditions. They are also essential to assess the feasibility
of clinical trials and to facilitate their planning. Established
at a national and especially an international level, regis-
tries can greatly assist in the identification of suitable
patients to support enrollment and to ensure that clinical
trials are adequately powered.51e55 Contact registries
inform patients and their families of clinical research
studies.
In the United States, the Rare Lung Disease Consortium
(RLDC) is a network of cooperating clinical and research
centers and patient-support organizations that are working
with the NIH in order to accelerate clinical research and
improve the delivery of medical care to individuals affected
by rare lung diseases. Toward this aim, the RLDC serves as
a database for research information on a variety of rare
lung diseases, as well as being a contact registry. This
contact registry, which was set up as a result of patient
pressure and reflects their eagerness to participate in
clinical trials, has proven successful in identifying patients
eligible for different trials evaluating the treatment of AAT
deficiency. This approach has allowed the limited number
of patients available to be allocated to different studies.
The Alpha One International Registry (AIR) captures
information on individuals with AAT deficiency from 4
continents and 21 countries (15 of which are in Europe).56
The Alpha-1 Foundation Research Registry is available to
assist clinical trial enrollment in North America.57 Registries
for CF and PAP are organized on a national level, and, in
addition, the European Cystic Fibrosis Society Patient
Registry holds data on more than 20,000 CF patients from
16 countries.58 A patient/clinician LAM registry has been
recently established in the United States.59
Registries not only help researchers identify and recruit
patients who are eligible for participation in future
research into rare diseases, but are also a source of longi-
tudinal data.60,61 Although establishing a registry is rela-
tively simple and inexpensive, the cost of maintaining it can
be prohibitive, especially as funding is often limited.
Registries should not just be a list of patients, but be as
comprehensive a source of information as possible. The
linking of registries with tissue banks to assist with the
investigation of rare diseases should also be considered.Reimbursement
At present, there is a lack of alignment between licensing
and reimbursement processes from an early stage of drug
development. To address this, a closer relationship is
needed between clinicians, drug developers, regulators,
and payers, be it insurance companies or national health-
care systems. The 2000 EU legislation concerning orphan
medicinal products stated that “patients suffering from
rare conditions are entitled to the same quality of treat-
ment as other patients,”13 and this is reflected in the
centralization of marketing authorization in all 27 EU
member states. This equal entitlement, however, does not
apply to the pricing and reimbursement of orphan medical
Improving access of rare lung disease therapies in Europe 765products between the different Member States.62 Negotia-
tion of pricing and reimbursement policies are delegated to
individual countries. There may also be differences at
a regional level, and individual hospitals may have varying
opinions on how to distribute their financial resources and
how much of their total budget they are prepared to devote
to the provision of orphan medicinal products. Such treat-
ments are often considered to be disproportionately
expensive. These differences are difficult to justify on
medical grounds. An increased speed of approval for orphan
drugs (for example, involving surrogate endpoints and
shorter clinical trials) could lower their cost.
Perspectives
Taking into consideration the issues discussed in this paper
we offer the following perspectives.
Communication
Greater collaboration and communication at all levels is
crucial to ensure the increased availability of orphan
medicinal products for a wider range of rare diseases. A
step forward is the development of a unified orphan drug
designation application form for both the FDA and EMA.63
Consistency in the definition of validated study endpoints
and approval of surrogate markers needs to be achieved
through discussion with the regulatory authorities. Phar-
maceutical companies, clinicians, regulators, payers, and
patients should be involved in the regulatory process on
a continuous basis and in the subsequent rulings on pricing
and reimbursement.
Patient organizations
Patient advocacy developed in the United States in the
1970s and became a driving force in the introduction of the
US Orphan Drug Act. These groups have evolved and, being
politically active and well-informed, subsequently formed
collaborative partnerships with researchers studying rare
diseases, government officials responsible for medical
research, and the FDA. Patient advocacy is less well
developed in Europe and patient communities are less
empowered. Some European patient advocacy groups are,
however, very successful with fundraising; they are now
becoming proactively involved in research and fund
research programs.
In CF, the role of patient organizations in Europe is
relatively well advanced and there is good collaboration
between patients, investigators, and drug developers. The
CF Trust in the United Kingdom is a powerful voice, and
following a campaign by the Trust, newborn screening was
implemented throughout the United Kingdom in 2007. The
rarer the disease, the less the power, but the stronger
groups could lead the way forward. Childhood interstitial
lung disease is an example where transatlantic cooperation
could benefit from the experience of patients in the United
States. In PAP, leaders in each country have been brought
together, resources pooled, and a global registry can now
be created. Through the Rare Lung Disease Consortium, two
new patient foundations have been started. Patientpressure to speed up the progression of drugs has been
seen, for example, in the area of HIV therapy. This example
of patient influence could be leveraged in the case of rare
lung diseases. Patients with LAM came together to raise
funding for the MILES trial, and demonstrated their will-
ingness to be enrolled into the study.64
One of the mandates of EURORDIS, a nongovernmental,
patient-driven alliance of patient organizations represent-
ing more than 461 rare disease patient organizations in over
45 countries in Europe, is to encourage the emerging
networks to become well-structured, disease-specific
federations at a pan-European level with a program called
Rare!Together.65 The aim is that newly formed patient
organizations will receive advice from a mentor with
extensive experience in setting up and running patient
organizations. Two patient groups e congenital heart
disease and hereditary spastic paraplegia e have been
selected to start the program.66 EURORDIS, however, does
not provide funding, so there is still the issue of fundraising.
The more active patient advocacy groups are addressing
such issues as local access to treatment (the postal code
lottery)67; other groups may also adopt this approach and
lobby for better access to drugs.
Workshops
European patient groups could take as an example the US
Alpha-1 Foundation. Since its inception, the Foundation has
fostered collaborations with investigators throughout the
United States and Europe, working closely with the NIH and
the FDA. Among its activities are NIH-funded twice-yearly
workshops, set up to consider specific topics, such as the
identification of biomarkers. Another example is the
American Thoracic Society (ATS) Public Advisory Round-
table. During the annual International Conferences of the
ATS, patients can recount their experiences at this forum.
There is the potential for similar activities in Europe under
the auspices of a European organization; for example,
funding for workshops could be sought from the European
Research Council, and a European Respiratory Society-
sponsored workshop organized that includes patient advo-
cacy groups. Such initiatives could help to set up a coalition
of respiratory disease leaders from the patient community.
The EMA organized a workshop on the development of
therapy for Duchenne muscular dystrophy, and the
requirements of regulatory agencies were addressed at this
meeting. The possibility of holding a workshop on specific
aspects of a rare lung disease could be explored with the
EMA. The EMA has recently created a respiratory disease
drafting group whose tasks include the drafting of guide-
lines and providing support for scientific advice.
EU Task Force
Finally, a major goal would be the formation of an EU Task
Force, composed of physicians and respiratory experts from
various countries, as well as officers of the EMA, to consider
the treatment of rare lung diseases. This task force would be
a permanent group meeting on a regular basis and would
ultimately lead to the publication of a consensus document.
Our perspectives are summarized in Table 4.
Table 4 Perspectives to improve the access to therapies
for rare lung diseases in Europe.
 Greater collaboration and communication at all levels,
including all stakeholders (patient groups, physicians,
drug developers, regulators, payers)
 Integration across countries and continents
 New clinical trial protocols can be developed and
agreement reached on appropriate outcome measures
 Better organization of patients in Europe to improve
patient empowerment and raise more interest in rare
lung diseases
 Raise European funding to support initiatives, such
as regular workshops
 ERS-sponsored course/workshop dedicated to rare
lung diseases that includes patient advocacy groups
 Use the limited number of patients wisely; learn from
the model of the Rare Lung Diseases Consortium in the
United States
 Set up an expert group of respiratory physicians within
the EMA
 Create and strengthen European task forces on rare
diseases aimed at writing consensus documents
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Orphan drug legislation encourages research into rare lung
conditions; however, there are many challenges in Europe
for the development of new treatments for these diseases.
The United States led the way in the introduction of such
legislation and provided the impetus for European Orphan
Medicine Products Regulation. Further lessons can be
learned from the United States in raising awareness and
improving the evaluation of therapies for rare lung
diseases. Patients with rare diseases deserve the same level
of evidence as those with common diseases whenever this is
possible. However, this level of expectation should not
preclude the approval of drugs likely to be of benefit but
where the criteria required for common conditions cannot
be met. It is important, therefore, to achieve the right
balance and ensure that should an effective or potentially
effective therapy become available, its development is
progressed and patient access to this treatment is not
delayed.
There should be increased communication with the EMA
involving clinicians, researchers, and drug developers, and
full use must be made of the scientific advice available. If
pharmaceutical companies interact with the EMA early on
in the development of their products then the prospects of
a positive outcome improve. Better clinical trial protocols
can be developed and agreement reached on appropriate
outcome measures. Insufficient financial support is a major
hurdle, both at a national and pan-European governmental
level. There is a clear need for more research grants and
the provision of funds for maintenance of registries, as well
as tax exemptions for the research and development of new
orphan medicinal products. Many processes are also
hampered by limited communication between all inter-
ested parties; patients, researchers, clinicians, developers
of drugs, and payers need to interact more, not just ata national or even European level. An alignment of
requirements for the licensing and reimbursement of drugs
would also be a huge step forward.
Patients interested in participating in clinical research
can be located through registry initiatives and then through
clinical networks and alliances. Patients are a valuable
resource but are not solely the participants in clinical trials
and the individuals who consult physicians. They have the
potential to exert considerable pressure on researchers,
the regulatory authorities, and governments to increase
attention to rare lung diseases and stimulate the greater
availability of therapies to provide them with a better
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